| Biologic Agents |
Targeted biologic therapies
offer new avenues of treatment options for patients
with advanced/metastatic breast cancer. In particular,
HER2-targeted agents play a definitive role in
improving survival in patients with metastatic
breast cancer. In addition to single-agent activity,
these agents show potent synergy with many chemotherapy
agents in this setting. Agents targeting
the EGFR and VEGF pathways are also under investigation,
as are other novel agents targeting distinct
cellular growth or survival pathways. Alone or
in combination with conventional cytotoxics,
these agents promise to add to the number of
active treatment options. Current
challenges include optimizing patient selection,
integrating these new agents into traditional
chemotherapy regimens, and determining the most
effective combination regimens with the least
toxicities. |
| |
Interactive Case Study
|
 |
June 2007
1 AMA PRA Category
1 Credit™
Expiration date: June 30, 2008
- Treatment Options for HER2-Negative Metastatic Breast Cancer
|
|
| |
LECTURES
|
| In-Depth Tumor Board: Biologic Therapy for Breast Cancer
|
| Receptor-Based Therapeutics: An Interactive Exposé
|
Sixth International Symposium on Supportive Care in Oncology: Cancer Management in the Era of Targeted Agents
February 22-23, 2008
New York, NY |
|
Breast Cancer Highlights: Updates from the 2007 San Antonio Breast Cancer Symposium
January 31, 2008
Kansas City, MO |
|
Breast Cancer Highlights: Updates from the 2007 San Antonio Breast Cancer Symposium
January 24, 2008
Atlanta, GA |
|
Contemporary Trends in Chemotherapy for Advanced/Metastatic Breast Cancer
December 14, 2007
San Antonio, TX
|
|
|
Controversies in Biologic Therapy of Breast Cancer
September 7, 2007
San Francisco, CA |
|
2 AMA PRA Category
1 Credits™
Expiration date: September 24, 2008 |
Beyond Taxanes: New Chemotherapeutic Options for Patients With Refractory Metastatic Breast Cancer
September 7, 2007
San Francisco, CA |
|
2 AMA PRA Category
1 Credits™
Expiration date: September 24, 2008 |
| New Paradigms in the Biologic Therapy of Breast Cancer: Translating Advances in Molecular Biology Into Improved Patient Outcomes
|
| Emerging Pathways With Therapeutic Potential in Cancer
|
| Tailoring ErbB-Directed Therapies for Optimized Care of Breast Cancer Patients
|
|
Emerging Strategies in Breast Cancer: Targeting Tomorrow’s Therapies Today
May 12, 2007
Boston, MA
- Using Genomic Tools in Patient Selection for Adjuvant Chemotherapy
- Proteomics, Kinomics, and Other Predictive Tools
- Next-Generation Adjuvant Chemotherapies: Integrating Antimetabolites and Biologics
- Epothilones
- Novel Vinca Alkaloids and Other Mictrotubule-Targeting Agents
- Targeting HER2 in Early Breast Cancer: Optimizing Therapy
- Dual ErbB1/ErbB2 Kinase Inhibitors
Targeting the VEGF/VEGFR Pathway: Antibodies, Small-Molecule TKIs, Decoy Receptors, and Other Novel Approaches
- Mechanisms of Endocrine Resistance and New Targets for Clinical Research
- Nausea and Vomiting - Emerging Agents and New Formulations
- Targeting RANK/RANKL, Cathepsin K, TGF-Beta and Other New Signaling Pathways
- Novel Agents for the Treatment or Prevention of Hematopoietic Adverse Events (Neutropenia, Thrombocytopenia, and Anemia)
|
| |
Current Trends in Breast Cancer
January 13, 20-February 3, 24, 2007
2007 Series
- New Developments in Adjuvant Chemotherapy
- Controversies in Adjuvant Hormonal Therapy
- Adjuvant HER2-Directed Therapy: Candidates and Practical Management
- Novel Preoperative Therapy Strategies
- Treatment Insights Based on Molecular Subtypes and Novel Diagnostics
- New Insights Into Optimizing Local Control
- Evolving Chemotherapies and Hormonal Therapies for Metastatic Breast Cancer
- Novel Biologic Agents With Clinical Promise
- Management of Therapy-Related Toxicities
- Focus on the Host: Evolving Concepts
|
|
|
Rapid Reviews in Oncology: Focus on Breast Cancer
Innovative Learning Programs
- Optimizing Adjuvant Therapy of Surgically Resected Breast Cancer
- Optimal Use of Biologic Agents in Metastatic Breast Cancer
- Question-and-Answer Session and Case-Based Discussion
|
|
|
Controversies in Breast Cancer Adjuvant and Neoadjuvant Therapy 2006
September 8-10, 2006 |
- Key Diagnostic Assessments in Breast Cancer
- Evolving Local Control Issues in Breast Cancer
- Treatment of Hormone Receptor–Positive Breast Cancer
- Adjuvant Treatment of HER2-Driven Breast Cancer
- Treating ER, PR, HER2-Negative Breast Cancer
- Lifestyle, Genetics, and Breast Cancer Outcome
|
|
5th Annual International Congress on the Future of Breast Cancer
August 3-6, 2006
- Best of Breast Cancer Research
- Optimizing Endocrine Therapy
- Molecular Mechanisms of Endocrine Resistance
- Supportive Care Breakfast Symposium
- Predictive and Prognostic Factors for Adjuvant Therapy
- Emerging Chemotherapy Strategies
- Targeting the HER Axis in Breast Cancer
- Targeting Angiogenesis in Breast Cancer
- New Agents Breakfast Symposium
- Impact of Local Control on Overall Outcomes
- Maintaining Bone Health
- Optimizing Chemotherapy
- Practical Issues in Breast Cancer Treatment
- Breast Cancer Genetics and Biology
|
|
|
|
|
| |
PUBLICATIONS
|
 |
Vol. 3, No. 1
1 AMA
PRA Category 1 Credit™
Expiration date: June 6, 2009
-
Management of Platinum-Resistant Ovarian Cancer
|
|
 |
May 2008
1 AMA
PRA Category 1 Credit™
Expiration date: June 6, 2009
-
Management of Platinum-Resistant Ovarian Cancer
|
|
 |
April 2008
1 AMA
PRA Category 1 Credit™
Expiration date: June 4, 2009
- Targeting Growth Factor Receptors: Current Impact and Future Potential
- Therapeutic Applications of Angiogenesis-Based Therapies
|
|
 |
Vol. 6, No. 1
1 AMA
PRA Category 1 Credit™
Expiration date: May 5, 2009
- ErbB TKIs in ErbB2-Positive IBC
|
|
 |
Vol. 5, No. 2
1 AMA
PRA Category 1 Credit™
Expiration date: May 6, 2009
- Lapatinib/Capecitabine for ErbB2-Positive Advanced Breast Cancer
- Cardiac Safety of Doxorubicin/Cyclophosphamide Followed by Paclitaxel ± Trastuzumab
- Phase II Study of Predictive Biomarker Profiles With Lapatinib in IBC
- Trastuzumab/Tanespimycin in Trastuzumab-Refractory ErbB2-Positive Breast Cancer
|
|
 |
February
2008
1 AMA
PRA Category 1 Credits™
Expiration date: March 10, 2009
- Single vs. Combination Therapy: Which Agents and What Clinical Situation?
- Chemotherapy and Biologically Targeted Agents: Synergy and Side-Effect Profile
- LABC as aModel for the Study and Optimization of Chemotherapeutic Regimens
- Protein and Genetic Markers in Deciding Optimal Chemotherapy
|
|
 |
Vol. 8, Suppl. 1
1.5 AMA
PRA Category 1 Credit™
Expiration date: March 3, 2009
- Advances in Chemotherapy and Supportive Therapy for Breast Cancer
|
|
 |
Vol. 4, No. 12
1 AMA
PRA Category 1 Credit™
Expiration date: March 3, 2009
- Treatment of HER2-Positive/Hormone Receptor–Positive Metastatic Breast Cancer With Endocrine Therapy Plus HER2-Targeted Therapy
|
|
 |
Vol. 5, No. 10
1 AMA PRA
Category 1 Credit™
Expiration date: December 26, 2008
- Treatment of a Patient With Relapsed ErbB2-Positive Metastatic Breast Cancer With Lapatinib
|
|
 |
December 2007
1 AMA PRA
Category 1 Credit™
Expiration date: December 22, 2008
- Who Needs Adjuvant HER2-Targeted
Therapy?
- Novel Therapies for HER2-Positive Breast
Cancer
- Confusion on the HER2 Front: Not All
Decisions
Are Black and White
- Inhibiting the Tumor Microenvironment
- Targeting Oncogene Addiction in Breast
Cancer:
Key Pathways and Novel Targets
|
|
 |
Vol. 8, No. 4
1 AMA PRA
Category 1 Credit™
Expiration date: December 14, 2008
- Rationale and Clinical Data for Combined Inhibition of HER2 and Vascular Endothelial Growth Factor Receptor Pathways in Breast Cancer
- Genomic Rearrangements in Breast
Cancer: Clinical Implications
- Putative Breast Cancer Stem Cells as Therapeutic Targets
|
|
 |
December 2007
1 AMA PRA
Category 1 Credit™
Expiration date: December 14, 2008
- Controversies in Adjuvant Therapy: Treatment Options for Patients With Node-Negative, HER2-Positive, Early-Stage Breast Cancer
- Controversies in Metastatic Breast Cancer: Treatment Options for HER2-Positive Disease
- Controversies in Metastatic Breast Cancer: Treatment Options for HER2-Negative Disease
|
|
 |
Vol. 6, No. 1
1 AMA
PRA Category 1 Credit™
Expiration date: December 7, 2007
- Novel Strategies for Treating Ovarian Cancer
- Emerging Monoclonal Antibodies for the Treatment
of HER2-Positive Breast Cancer
|
|
 |
November 2007
1 AMA
PRA Category 1 Credit™
Expiration date: November 20, 2007
- Targeting Signaling Pathways to Inhibit Cancer Growth
- Targeting the MAP/MEK and PI3K/Akt Pathways
- Novel Small-Molecular Inhibitors Targeting VEGFR in Breast Cancer
- Vaccines in Lung Cancer
- Novel Immunologic Targets in Metastatic Melanoma
- Combining Targeted Agents to Improve Therapeutic Efficacy
|
|
 |
November 2007
1 AMA PRA
Category 1 Credit™
Expiration date: November 20, 2008
- Optimizing Adjuvant Therapy With HER2-Targeted MoAbs
- Clinical Utility and Future Prospects of Small-Molecule HER TKIs
- Breast Cancer Resistant to HER2-Targeted Therapies
- Clinical Utility and the Future of Angiogenesis Inhibitor Therapy
- Emerging Applications of IGF-1R–Targeted Therapy
|
|
 |
November 2007
1 AMA PRA
Category 1 Credit™
Expiration date: November 20, 2008
- HER2-Targeted Therapy in Early-Stage Breast Cancer
- Emerging Targeting Agents in HER2+ Breast Cancer
- Angiogenesis Inhibition in Advanced Breast Cancer
- Multiplying the Benefits: Novel Combinations of Targeted Agents
- c-Myc Amplification and Other Genetic Alterations in HER2+ Breast Cancer
|
|
 |
Vol. 5, No. 8
1 AMA PRA
Category 1 Credit™
Expiration date: November 20, 2008
- Paclitaxel Formulations in MBC
|
|
 |
August
2007
1 AMA
PRA Category 1 Credit™
Expiration date: August 31, 2008
- Increasing the Therapeutic Index of Traditional Chemotherapeutics
- Role of the Tumor Stroma in Breast Cancer and Treatment
- Immune-Mediated Antitumor Effects With Antibody Therapy
|
|
 |
August
2007, Vol. 8, No. 5
1 AMA PRA
Category 1 Credit™
Expiration date: August 31, 2008
- Adjuvant Chemotherapy With or Without Trastuzumab in HER2-Positive Breast Cancer
- First-line Paclitaxel/Lapatinib in MBC
- Phase II Trial of First-line Capecitabine/Bevacizumab in MBC
- Phase II Trial of First-line Docetaxel With or Without Axitinib in MBC
- Phase II Trial of Pertuzumab/Trastuzumab in HER2-Positive MBC
|
|
 |
July
2007, Vol. 4, No. 4
1 AMA PRA
Category 1 Credit™
Expiration date: July 31, 2008
- Treatment of a Patient With
ErbB2-Positive MBC With a Taxane/Platinum/ErbB2-Targeted
Regimen
|
|
 |
June
2007, Vol. 5, No. 6
1 AMA PRA
Category 1 Credit™
Expiration date: July 31, 2008
- ErbB2-Targeted Therapy in
Heavily Pretreated IBC
|
|
 |
June
2007, Vol. 8, No. 2
1 AMA PRA Category
1 Credit™
Expiration date: June 30, 2008
- Recent Advances in the Treatment
of ErbB2-Positive Breast Cancer
- Efficacy and Safety of ErbB2-Targeted
Agents in the Adjuvant Setting
- Clinical Efficacy of ErbB2-Targeted
Agents in the Neoadjuvant Setting
- Predicting Response to ErbB2-Directed
Therapies: The Future of Biomarkers
- Novel Strategies in VEGF Inhibition
in Breast Cancer
|
|
 |
June
2007, Vol. 5, No. 1
1 AMA PRA Category
1 Credit™
Expiration date: June 30, 2008
- Lapatinib Plus Capecitabine for
HER2-Positive Advanced Breast Cancer
- ASCO/CAP Guideline Recommendations
for Human Epidermal Growth Factor
Receptor 2 Testing in Breast Cancer
- Predictors of Resistance to Preoperative
Trastuzumab and Vinorelbine for ErbB2-Positive
Early Breast Cancer
- Expression of p95HER2 and Response
to Anti-HER2 Therapies in Breast
Cancer
|
|
 |
May 2007
1.5 AMA PRA
Category 1 Credits™
Expiration date: May 31, 2008
- Adjuvant Nonanthracyclines in Breast Cancer
- HER Family Proliferation and Survival Signaling Pathways
|
|
 |
April
2007, Vol. 8, No. 2
1 AMA PRA
Category 1 Credit™
Expiration date: April 30, 2008
- Advances in the Use of Targeted
Therapies in the Treatment
of Breast Cancer
- Adjuvant Chemotherapy With
or Without Trastuzumab in HER2-Positive
Breast Cancer
- Biomarker Analysis of Lapatinib/Capecitabine
in Advanced or Metastatic HER2+ Breast
Cancer
- Lapatinib in Neoadjuvant Therapy
for IBC
- First-line Docetaxel/Capecitabine/Bevacizumab
in MBC
- Ongoing Trials of Angiogenesis
Inhibitors in MBC
|
|
 |
May
2007, Vol. 2, No. 4
1 AMA PRA
Category 1 Credit™
Expiration date: May 31, 2008
- Angiogenesis Inhibition
in Breast Cancer
- Novel Antiangiogenic Agents
in Prostate Cancer
- Mechanisms of Antiangiogenic
Cancer Therapy
|
|
 |
April
2007, Vol. 5, No. 8
1 AMA PRA
Category 1 Credit™
Expiration date: April 30, 2008
- Albumin-Bound Paclitaxel/Bevacizumab
in MBC
|
|
 |
April
2007, Vol. 4, No. 1
1 AMA PRA
Category 1 Credit™
Expiration date: April 30, 2008
- Treatment of a Patient With
ErbB2-Positive MBC
|
|
 |
April
2007, Vol. 1, No. 1
1 AMA PRA
Category 1 Credit™
Expiration date: April 30, 2008
- Alternative Strategies for Targeting HER2 in Breast Cancer
- Immunotoxins in Breast Cancer Therapy
|
|
 |
April
2007, Vol. 9, No. 6
1 AMA PRA
Category 1 Credit™
Expiration date: April 30, 2008
- Targeting the ErbB Family
in Breast Cancer: Antibodies
and Small Molecules
- Biologic Agents for Advanced
ErbB2-Positive Breast Cancer
- Improving the Cardiac Safety
of ErbB2 Inhibition
|
|
 |
April
2007, Vol. 5, No. 7
1 AMA PRA
Category 1 Credit™
Expiration date: April 30, 2008
- Lapatinib in ErbB2-Positive
CNS Metastases
|
|
 |
March
2007
3.5 AMA PRA Category 1
Credits™
Expiration date: March 31, 2008
- Optimizing Breast Cancer Therapy: Integrating Biologic Approaches Into Everyday Practice
|
|
 |
February
2007, Vol. 5, No. 5
1 AMA PRA Category 1
Credit™
Expiration date: February 29, 2008
- Neoadjuvant Treatment of ErbB2-Positive LABC
|
|
 |
February
2007, Vol. 1, No. 1
1.75 AMA PRA Category
1 Credits™
Expiration date: February 29, 2008
- Targeted Therapies for Breast Cancer
|
|
 |
January
2007, Vol. 5, No. 3
1 AMA PRA Category 1
Credit™
Expiration date: January 2008
- Treatment of a Patient with HER2-Positive
Metastatic Breast Cancer: Options in HER2-Directed
Therapy
|
|
| |
